Treatment News : Very Early HIV Treatment in Monkeys Limits Viral Reservoir

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » March 2014

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

March 20, 2014

Very Early HIV Treatment in Monkeys Limits Viral Reservoir

CROI 2014The initial days of infection with a virulent version of SIV, the simian cousin of HIV, represent a crucial window during which starting antiretrovirals (ARVs) can greatly limit the future size of the viral reservoir in monkeys, the National AIDS Treatment Advocacy Project (NATAP) reports.

Researchers intravenously infected 22 macaque monkeys with SIVmag239 and then began them on ARVs after graduated periods of time had passed: Two monkeys began treatment after seven days, two monkeys started after 10 days, and 18 monkeys started after 42 days. The researchers presented their findings at the Conference on Retroviruses and Opportunistic Infections (CROI) in Boston.

After 32 weeks, the average amount of SIV DNA in the peripheral blood mononuclear cells (PBMCs—an indication of the size of the viral reservoir) in the two monkeys who started treatment after seven days was about 300 copies per 100 million cells. The two monkeys who started treatment after 10 days had an average measurement of about 3,000 copies per 100 million cells. The remaining monkeys had an average measurement of about 25,000 copies per 100 million cells.

There was a positive correlation between these PBMC reads at the 32-week mark and the monkeys’ peak viral loads. The two monkeys that received ARVs earliest had lower SIV DNA at 32 weeks in their lymph nodes, bone marrow and small intestine when compared with the other 20 monkeys.

To read the NATAP report, click here.

To watch the CROI webcast, click here.

Search: Viral reservoir, HIV, SIV, SIVmag239, macaque, monkey, National AIDS Treatment Advocacy Project, NATAP, Conference on Retroviruses and Opportunistic Infections, CROI.


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)

 
[Go to top]


Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    Drew949
    South Orange County
    California


    romanticseattle
    Tacoma
    Washington


    sefarady
    New York
    California


    robert12
    Queens
    New York
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Should "AIDS Walk" fundraisers be renamed?
Yes
No

Survey
PrEP Course

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.